Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Eigen will use the capital to apply their novel high-throughput platform toward the development of priming therapies. Their initial programs are focused on hematological malignancies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Josh Kopelman
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 08, 2022